GENITOURINARY CANCERS

The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced urothelial cancer patients, challenging traditional treatment durations.

UGN-103 shows promising 77.8% efficacy in treating recurrent low-grade bladder cancer, paving the way for a potential FDA approval.

Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.

XmAb819 shows promising antitumor activity and safety in advanced clear cell renal cell carcinoma, paving the way for future clinical advancements.

Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.

A new study reveals that combining TAR-200 with cetrelimab significantly improves treatment outcomes for muscle-invasive bladder cancer patients.

Results of a recent study reveal significant racial differences in renal cell carcinoma histology and outcomes, highlighting the need for ancestry-informed kidney care strategies.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

New research reveals enzalutamide combined with leuprolide significantly enhances survival rates in high-risk prostate cancer patients, setting a new standard of care.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

New trial results reveal capivasertib enhances survival in advanced prostate cancer, offering hope for patients with PTEN deficiency.

Fruquintinib plus sintilimab significantly enhances progression-free survival in advanced renal cell carcinoma, offering a promising second-line treatment option.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.